Panagora Asset Management Inc. cut its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 79.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,823 shares of the technology company’s stock after selling 41,864 shares during the quarter. Panagora Asset Management Inc. owned about 0.06% of Simulations Plus worth $309,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SLP. BNP Paribas Arbitrage SA raised its holdings in Simulations Plus by 59,875.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock worth $51,000 after buying an additional 2,395 shares during the period. Bank of America Corp DE raised its holdings in Simulations Plus by 65.7% during the 4th quarter. Bank of America Corp DE now owns 8,754 shares of the technology company’s stock worth $174,000 after buying an additional 3,471 shares during the period. Bailard Inc. acquired a new stake in Simulations Plus during the 2nd quarter worth about $208,000. Telos Capital Management Inc. acquired a new stake in Simulations Plus during the 2nd quarter worth about $221,000. Finally, Janus Henderson Group PLC acquired a new stake in Simulations Plus during the 2nd quarter worth about $238,000. Hedge funds and other institutional investors own 41.97% of the company’s stock.

In other Simulations Plus news, Director John Kenneth Paglia sold 690 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $37.86, for a total transaction of $26,123.40. Following the completion of the sale, the director now owns 2,112 shares of the company’s stock, valued at $79,960.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Walter S. Woltosz sold 24,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $36.22, for a total value of $869,280.00. The disclosure for this sale can be found here. Insiders own 31.57% of the company’s stock.

Several equities analysts have weighed in on the company. Zacks Investment Research raised Simulations Plus from a “hold” rating to a “strong-buy” rating and set a $37.00 target price on the stock in a research note on Friday, July 19th. ValuEngine cut Simulations Plus from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, BidaskClub cut Simulations Plus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday.

NASDAQ:SLP traded up $0.62 on Friday, hitting $35.26. 1,046 shares of the company’s stock traded hands, compared to its average volume of 114,977. Simulations Plus, Inc. has a 1 year low of $17.18 and a 1 year high of $41.95. The firm has a 50-day moving average price of $36.95 and a 200-day moving average price of $27.58. The company has a market cap of $585.90 million, a PE ratio of 69.81 and a beta of -0.35.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.02. The company had revenue of $9.94 million for the quarter, compared to analysts’ expectations of $9.85 million. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. Analysts predict that Simulations Plus, Inc. will post 0.46 earnings per share for the current fiscal year.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Featured Article: How dollar cost averaging works

Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).

Institutional Ownership by Quarter for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.